Therapeutic potential of TAS-102 in the treatment of gastrointestinal malignancies - Wikidata - wikimedia - TriplyDB

Therapeutic potential of TAS-102 in the treatment of gastrointestinal malignancies

Therapeutic potential of TAS-102 in the treatment of gastrointestinal malignancies

http://www.wikidata.org/entity/Q26777679

about

Current targeted therapies in the treatment of advanced colorectal cancer: a review Oral drugs in the treatment of metastatic colorectal cancer.Panitumumab interaction with TAS-102 leads to combinational anticancer effects via blocking of EGFR-mediated tumor response to trifluridine.5-Fluorouracil Treatment Alters the Efficiency of Translational Recoding.Contribution of equilibrative nucleoside transporter(s) to intestinal basolateral and apical transports of anticancer trifluridine.Radiosynthesis of the anticancer nucleoside analogue Trifluridine using an automated 18F-trifluoromethylation procedure.

P2860

Q26740067-C3273F61-7334-4DB7-A8AF-0663D3DA4CF4 Q30251387-F4A1A76B-5EF4-426B-99DE-3FB9563259CF Q41195691-D9B433CF-32BD-4F61-A3EE-3B56F4BA676A Q47148840-95CD3EA8-C7C7-40AF-AC0C-66F6D9DA59BF Q48153064-526329DF-2E21-4FC4-B8C9-86FAADFE7F06 Q52599217-382ECD64-8692-48DA-A6E5-BA896D6A90B6

P2860

Therapeutic potential of TAS-102 in the treatment of gastrointestinal malignancies

http://www.wikidata.org/entity/Q26777679

description

2015 nî lūn-bûn

@nan

2015 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Therapeutic potential of TAS-102 in the treatment of gastrointestinal malignancies

@ast

Therapeutic potential of TAS-102 in the treatment of gastrointestinal malignancies

@en

Therapeutic potential of TAS-102 in the treatment of gastrointestinal malignancies

@nl

type

label

Therapeutic potential of TAS-102 in the treatment of gastrointestinal malignancies

@ast

Therapeutic potential of TAS-102 in the treatment of gastrointestinal malignancies

@en

Therapeutic potential of TAS-102 in the treatment of gastrointestinal malignancies

@nl

prefLabel

Therapeutic potential of TAS-102 in the treatment of gastrointestinal malignancies

@ast

Therapeutic potential of TAS-102 in the treatment of gastrointestinal malignancies

@en

Therapeutic potential of TAS-102 in the treatment of gastrointestinal malignancies

@nl

P1433

Q26777679-CCDB9A29-E201-46FE-AC14-B99E9008ABC3

P1476

Q26777679-3A2E0D8A-0D80-4639-947D-2C85A6FEE27C

P2093

Q26777679-F83EB8B0-E84F-4D1A-A2CB-BA370F371D5D

P2860

Q26777679-06F38885-9098-492D-B02E-BB1C9C594689

Q26777679-09C38F86-C498-493E-8C7B-B9621741579B

Q26777679-0A04BC49-9FAB-496A-94C9-0E66F77AA4E3

Q26777679-0C264C91-D683-4D64-9D88-CFA06ED99CA6

Q26777679-0C4A3233-55DA-49FF-929A-325A59653B30

Q26777679-0DC87000-630C-4597-9269-A794B2C0F046

Q26777679-101C937F-27B6-4A53-8A75-5D71EC1F4BE3

Q26777679-1A8B87A1-0A54-4BD8-B88A-DCE3EFF6549A

Q26777679-206BC891-DEAB-40A7-8C6C-27DEE1AF2F26

Q26777679-2075A9F8-A9AF-44B8-8D26-B19F68773B10

P304

Q26777679-BA4CD6C1-35F6-4105-ADB3-68EAFA176A65

P31

Q26777679-1C0CE92C-6642-4B3B-85FB-2840D5DBB353

P356

Q26777679-CD6C6DD0-6A7D-46EB-8B60-4A8D8A00CE4C

P407

Q26777679-14A14BA5-AA91-4759-8E4F-1F7CB266FA91

P433

Q26777679-7DF15615-6F73-4F1E-B237-A4749A14E597

P478

Q26777679-C185BAD8-40EA-424C-9676-F9C544FB9CE4

P577

Q26777679-88881774-DAD8-46D4-BFB4-10517F8E6EA7

P698

Q26777679-A359DA45-FD79-4BD1-9748-A7C9DCED8175

P921

Q26777679-950F5940-D1BC-44F0-8E3E-6126105795E0

P932

Q26777679-1A20517F-DA28-4F78-8370-397E337C4935

P356

1758834015603313

P1433

Therapeutic advances in medical oncology

P1476

Therapeutic potential of TAS-102 in the treatment of gastrointestinal malignancies

@en

P2093

Godefridus J Peters

http://www.w3.org/2001/XMLSchema#string

P2860

Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism

Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer

The role of thymidine phosphorylase and uridine phosphorylase in (fluoro)pyrimidine metabolism in peripheral blood mononuclear cells

Purification and properties of an endothelial cell growth factor from human platelets

Structural analyses reveal two distinct families of nucleoside phosphorylases

Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours.

Phase I and II studies of 2'-deoxy-5-(trifluoromethyl)-uridine (NSC-75520).

Thymidylate synthase: a target for combination therapy and determinant of chemotherapeutic response in colorectal cancer.

A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.

The activity and expression of thymidine phosphorylase in human solid tumours.

P304

340-56

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1758834015603313

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2015-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26557901

http://www.w3.org/2001/XMLSchema#string

P921

tipiracil hydrochloride

P932

4622302

http://www.w3.org/2001/XMLSchema#string